-
Science & technology
Science & technology
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
- Overview
- Our pipeline
- Matrix-M™ adjuvant
- Recombinant, protein-based nanoparticle vaccine
- Global vaccine approval/authorization map
COVID-19 UPDATESNovavax has demonstrated its ability to quickly produce viable vaccine candidates for emerging infectious diseases such as COVID-19.
-
Who we are
Who we are
We are a biotechnology company committed to help address serious infectious disease globally through the discovery, development, and delivery of innovative vaccines to patients around the world.
Build your future with usJoin other passionately curious people who are bringing innovative vaccines to the world
-
Insights
Insights
Novavax is committed to accelerating the development of new and promising vaccines by building on years of study and experience.

Troy Morgan, JD
Senior Vice President,
Chief Compliance Officer
Chief Compliance Officer
Mr. Morgan is senior vice president, chief compliance officer, with responsibility for overseeing the strategic direction of the company’s comprehensive compliance program and to help ensure all global compliance requirements are met across the organization. Prior to joining Novavax in April 2021, he was chief compliance officer for EMD Serono, Inc., where he was responsible for building a global corporate compliance program that supported a broad range of therapies. Previously, he served in senior leadership roles at Merck KGaA, Sanofi, Biogen and at Bioverativ, where he was responsible for the development, implementation and management of a global compliance program. Mr. Morgan holds a Master of Laws from Pepperdine University, a Juris Doctorate from Faulkner University’s Jones School of Law, and a Bachelor of Science from Troy State University.